NEWS & EVENTS

Latest news and upcoming events

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio
01 Jul 2026

Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio

Upcoming events

  • Swiss Biotech Day 2026
    4 May - 5 May, 2026
    Zurich

    download

  • Goodwin’s European Summit: 2026 Emerging VC Leaders in Life Sciences
    20 -22 May, 2026
    Malta

    download

  • CFO Forum
    21 - 22 May, 2026
    Málaga

    download

  • BIOSPAIN
    29 September - 1 October, 2026
    Bilbao

    download
Anaconda Biomed Receives IDE Approval to Initiate Enrollment in the ATHENA Study<
17 Jul 2024

Anaconda Biomed Receives IDE Approval to Initiate Enrollment in the ATHENA Study

The study will assess the safety and effectiveness of mechanical thrombectomy using the ANA Funnel Catheter in combination with a stent retriever.
Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics Receives the Rosalind Franklin Society Special Award in Science<
16 Jul 2024

Dr Gloria Gonzalez-Aseguinolaza, Chief Scientific Officer of Vivet Therapeutics Receives the Rosalind Franklin Society Special Award in Science

Recognition of her pioneering gene therapy research
Memo Therapeutics ag appoints Paul Carter as Chairperson<
08 Jul 2024

Memo Therapeutics ag appoints Paul Carter as Chairperson

Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs<
26 Jun 2024

Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs

Nadia‘s expertise will help the company to progress our growing development pipeline of regenerative neural cell therapies.
Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy<
18 Jun 2024

Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy

RMAT designation follows positive data update from the ongoing Phase 1/2 clinical trial of NRTX-1001

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors<
14 Jun 2024

Mineralys Therapeutics Appoints Biopharmaceutical Executive Alexander M. Gold, M.D. to its Board of Directors

Dr. Gold is a cardiologist with more than 20 years of experience leading the development, approval, and commercialization of new therapies
Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXessTM, its restorative vascular access conduit<
13 Jun 2024

Xeltis receives IDE approval from FDA for initiation of US pivotal trial for aXessTM, its restorative vascular access conduit

The US-based pivotal trial follows strong 12-month data from the first-in-human trial in Europe

Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer<
11 Jun 2024

Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer

AJ has previously orchestrated and successfully executed strategy across multiple neurologic indications in various stages of development
Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy in compassionate-use study published in Brain<
11 Jun 2024

Leriglitazone halts disease progression in adult patients with early cerebral adrenoleukodystrophy in compassionate-use study published in Brain

Shows that leriglitazone can halt neuroinflammation and disease progression in adult patients with cALD at early disease stages
Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline<
29 May 2024

Adcendo ApS Announces Extension of Series A Financing to EUR 98M to Further Bolster its First-in-Class ADC Pipeline

Funds will be used to further strengthen growing pipeline of first in class ADC assets, including lead asset targeting uPARAP

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.